Consistently, data analysis from TCGA cohort also revealed higher TRIM25 expression in HCC patients was associated with poor clinical outcome as well as shorter disease-free survival times (Fig. 7f, g), which also observed in patients with breast cancer and lower grade glioma (Supplementary Fig. 6d, e). This evidence concerns the gene TRIM25 and breast carcinoma.